CD33 and renal cell carcinoma: In patients with RCC as well as with other cancers, granulocytic (G) MDSCs (CD33+, HLADR−, CD15+, CD14− dominate over monocytic (M) MDSCs (CD33+, HLADR−, CD15−, CD14+), as seen in mouse models [145,146].